Matches in SemOpenAlex for { <https://semopenalex.org/work/W2952062364> ?p ?o ?g. }
Showing items 1 to 68 of
68
with 100 items per page.
- W2952062364 abstract "Introduction: Immune suppression is a physiological phenomenon resulting from the cooperation of many actors, both humoral and cellular, which continuously interplay each other leading to the impairment of immune response. Immune suppression is necessary to avoid tissue damages and, ultimately, life-threatening situations which could be induced by the maintenance over time of the immune response. Unfortunately, during neoplastic disease, immune suppression favors tumor progression. Cell mediated immune suppression: Immune response starts with the antigens recognition by APCs, their presentation to naive T-cells and the reactive T-cells generation. Tumor has profound influence on the DCs maturation, and immature or partially matured DCs are largely represented in most tumors and mediate immune suppression. A second key-point leading to the impairment of the immune response is the capability of effector T cells to cross the vascular endothelium to reach their targets. Thus, endothelial cells may represent powerful mediators of immune suppression, selecting the populations of cells which can cross the barrier and preventing homing, or directly killing those that must be stopped. The third and most important area of immune-suppression is the local tumor microenvironment (TME) where the plasticity of immune cells and stromal cells allows the polarization toward a Th2 response. Indeed, tumor cells may directly secrete immune suppressive cytokines and chemokines prone to impair immune attack. In addition, the persistence of inflammation changes in the TME, such as pH modification and hypoxia, may impair the activity of effector T cells, both directly and indirectly. Targeting of immunosuppressive cells: There are two main opportunities to target immunosuppressive cells. It is possible target specific cell lines directly using classic anticancer drugs. For example cyclophosphamide and gemcitabine, can directly target Treg and MDSC respectively. It is also possible to exploit the plasticity of immune cells to reprogram them towards a Th1 response. For example, inhibition of PD-1/PD-L1 axis prevents Tregs (iTregs) induction leading to the reduction of this population into the TME. Translational data on targeting immunosuppressive cells will be discussed." @default.
- W2952062364 created "2019-06-27" @default.
- W2952062364 creator A5009199625 @default.
- W2952062364 creator A5015046932 @default.
- W2952062364 creator A5050361464 @default.
- W2952062364 date "2018-10-20" @default.
- W2952062364 modified "2023-09-23" @default.
- W2952062364 title "Breaking the brake: targeting the immunosuppressive cells to optimize immunotherapy of cancer" @default.
- W2952062364 doi "https://doi.org/10.18416/cio.2018.1810002" @default.
- W2952062364 hasPublicationYear "2018" @default.
- W2952062364 type Work @default.
- W2952062364 sameAs 2952062364 @default.
- W2952062364 citedByCount "0" @default.
- W2952062364 crossrefType "journal-article" @default.
- W2952062364 hasAuthorship W2952062364A5009199625 @default.
- W2952062364 hasAuthorship W2952062364A5015046932 @default.
- W2952062364 hasAuthorship W2952062364A5050361464 @default.
- W2952062364 hasConcept C13373296 @default.
- W2952062364 hasConcept C157081693 @default.
- W2952062364 hasConcept C203014093 @default.
- W2952062364 hasConcept C2776090121 @default.
- W2952062364 hasConcept C2776107976 @default.
- W2952062364 hasConcept C2776914184 @default.
- W2952062364 hasConcept C2777701055 @default.
- W2952062364 hasConcept C49382859 @default.
- W2952062364 hasConcept C83464605 @default.
- W2952062364 hasConcept C86803240 @default.
- W2952062364 hasConcept C8891405 @default.
- W2952062364 hasConceptScore W2952062364C13373296 @default.
- W2952062364 hasConceptScore W2952062364C157081693 @default.
- W2952062364 hasConceptScore W2952062364C203014093 @default.
- W2952062364 hasConceptScore W2952062364C2776090121 @default.
- W2952062364 hasConceptScore W2952062364C2776107976 @default.
- W2952062364 hasConceptScore W2952062364C2776914184 @default.
- W2952062364 hasConceptScore W2952062364C2777701055 @default.
- W2952062364 hasConceptScore W2952062364C49382859 @default.
- W2952062364 hasConceptScore W2952062364C83464605 @default.
- W2952062364 hasConceptScore W2952062364C86803240 @default.
- W2952062364 hasConceptScore W2952062364C8891405 @default.
- W2952062364 hasIssue "1" @default.
- W2952062364 hasLocation W29520623641 @default.
- W2952062364 hasOpenAccess W2952062364 @default.
- W2952062364 hasPrimaryLocation W29520623641 @default.
- W2952062364 hasRelatedWork W157381717 @default.
- W2952062364 hasRelatedWork W1973389945 @default.
- W2952062364 hasRelatedWork W2000816527 @default.
- W2952062364 hasRelatedWork W2022996006 @default.
- W2952062364 hasRelatedWork W2026282548 @default.
- W2952062364 hasRelatedWork W2066982596 @default.
- W2952062364 hasRelatedWork W2093276391 @default.
- W2952062364 hasRelatedWork W2130799167 @default.
- W2952062364 hasRelatedWork W243322555 @default.
- W2952062364 hasRelatedWork W2582971374 @default.
- W2952062364 hasRelatedWork W2761606529 @default.
- W2952062364 hasRelatedWork W2774545971 @default.
- W2952062364 hasRelatedWork W2798853371 @default.
- W2952062364 hasRelatedWork W2805173199 @default.
- W2952062364 hasRelatedWork W2946663348 @default.
- W2952062364 hasRelatedWork W3015763287 @default.
- W2952062364 hasRelatedWork W3159811519 @default.
- W2952062364 hasRelatedWork W3204574820 @default.
- W2952062364 hasRelatedWork W75192572 @default.
- W2952062364 hasRelatedWork W934444297 @default.
- W2952062364 hasVolume "1" @default.
- W2952062364 isParatext "false" @default.
- W2952062364 isRetracted "false" @default.
- W2952062364 magId "2952062364" @default.
- W2952062364 workType "article" @default.